Biotech IPOs: what are we AIMing for?

Join the BIA, Stifel and colleagues from the investment sector at this informal networking breakfast on 28 September.

This panel event will discuss the performance of AIM, NASDAQ and other stock exchanges in the financing of UK biotech companies. Which exchanges allow UK companies to raise the most cash, achieve greatest liquidity and attract more follow on funding, and why? In recent years the biggest UK biotech IPOs have been on NASDAQ, is AIM just in a slump or is there a fundamental problem that the UK needs to address? And what impact will recent changes to the Hong Kong exchange rules, which now allow unprofitable biotechs to list there, have on the UK ecosystem?   

Free to attend, but please note open to investors and fund managers, the finance community, and BIA member biotech C-level only.


8.00 - 8.30 Registration, networking breakfast

8.30 - 8.40 BIA finance update

8.40 - 9.30 Panel discussion

9.30 - 10.00 Networking


 Steve Bates OBE
Neil Clark

Neil Clark

Chief Executive Officer , Destiny Pharma

James Clark

James Clark

Head of Tech and Lifesciences, Primary Markets , London Stock Exchange

Andrew Davis

Andrew Davis

Head of Investment and Promotion , Invest Hong Kong

Jonathan Senior

Jonathan Senior

Director, Healthcare , Stifel

Asaf Homossany

Asaf Homossany

Managing Director - EMEA , NASDAQ



150 Cheapside 





Free for members and non-members


BIA Annual Supporters